Elecsys® GAAD

Elecsys® GAAD test for the aid in diagnosis of early-stage HCC

Icon
Tune in to help save lives

Heptocellular Carcinoma (HCC) is a "silent killer". It develops unseen, often only to be found when it’s too late to save patients. It is already the third leading cause of cancer death,1 and the global incidence of HCC is increasing, especially in developed countries.2


But it doesn’t have to be that way. We refuse to let it continue as a "silent killer".
We’re turning up the volume on HCC.


Healthcare is rapidly shifting, towards more personalised care that’s more in tune with patients, embracing digital technologies that enable new possibilities. At Roche, we are shaping a new class of diagnostic algorithms.


Introducing the Elecsys® GAAD in-vitro diagnostic multivariate index assay. It will be the only IVD-approved algorithm to help you diagnose early stage HCC and save lives. Combining Elecsys® AFP and Elecsys® PIVKA-II assay results, along with gender and age, Elecsys® GAAD communicates patients’ risk factor clearly, so you may be able to evaluate earlier and save more lives.


It’s simple and intuitive to use, and can be adapted to your current workflow, so there will be no disruption to you.

clear

Crystal clear

Elecsys® GAAD gives you an easy-to-understand and accurate risk score3

icons approved

IVD approved3

Elecsys® GAAD is the only currently approved digital tool for aid in diagnosis of early stage HCC

icon integrated

Can be seamlessly integrated

Can be integrated to your LIS easily with your current workflow

icon partnership

Committed partner

Trust Roche to help STOP Chronic Liver Disease

Elecsys GAAD

HCC detection that’s in sync with your workflow

Ending the silence

HCC is often diagnosed in its advanced stages – when 5 year survival rates can be as low as 5%4 – because early stages are asymptomatic, and it can be difficult to gauge each patient’s risk factor. 

HCC develops in patients with chronic liver disease5, but this can happen at any stage over up to 30 years.6 Surveillance measures like ultrasound and MRI are useful, but expensive to keep running. 

Amplifying your confidence

We engineered the Elecsys® GAAD to be truly simple and speedy to set-up and use. However, you’re never alone. We have created a range of support materials to aid your interpretations and ensure that you are always confident in your next step.

Contact us to Register your Interest

Amplifies the effectiveness of AFP

Ultrasound will always be a useful tool in HCC diagnosis. However, it has its limitations; readings can be compromised by obesity, fibrotic changes, and even the quality of device or user experience.7-9

But combining ultrasound with HCC-specific biomarkers, as Elecsys® GAAD does, increases sensitivity for detecting early-stage HCC.10

icon ultrasound

Ultrasound alone11 45%

icon sensitivity

Elecsys® GAAD High sensitivity is provided3

icon ultrasound plus

Ultrasound + AFP11 63%

Instant result of GAAD score

Elecsys® GAAD is a simple yet sophisticated algorithm. 

All you need to do is enter 4 pieces of patient data3 into the calculator, and in an instant you’ll be given a result: a risk-factor score from 0-10, to accurately predict how likely that patient is to develop HCC.3 The score is accompanied by a built-in result interpretation to help guide your next clinical decision.

icon age

Age

icon AFP result

AFP result

icon gender

Gender

icon PIVKA-II result

PIVKA-II result

Elecsys GAAD  treatments
References

  1. Kao Wei-Yu, et al. Medicine Baltimore 2015;94(43):e1929. 
  2. Fitzmaurice T, et al. JAMA Onco 2017;3(12):1683–1691.  
  3. Elecys GAAD Method Sheet. Reference: 09342192001.
  4. El-Serag HB, et al. Ther Adv Gastroenterol 2011;4(1):5–10.  
  5. Llovet JM, et al. Nat Rev Dis Prim 2016;2:16018. 
  6. El-Serag HB, et al. Hepatology 2002;36:S74–S83. 
  7. EASL Clinical Practice Guidelines: Management of hepatocellular carnoma. Journal of Hepatology 2017;69(1):182–236.  
  8. Simmons O, et al. Ailment Pharmacol Ther 2017;45:169–177.  
  9. Sherman M. Hepat Oncol 2014;1(2):161–163. 
  10. Tzartzena K, et al. Gastroenterology 2018;145(6):1706–1718.  
  11. Yan JD, et al. Cancer Epidemiol Biomarkers Prev 2019;28(3):531–538.